Breaking News

Alkermes Provides Late-Stage CNS Pipeline Update

Phase III programs advance

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alkermes plc has reported new developments in its late-stage central nervous system (CNS) pipeline. The company has added aripiprazole lauroxil two-month, which is currently in Phase III development, to its portfolio of atypical antipsychotics for the treatment of schizophrenia. If approved, aripiprazole lauroxil two-month would be the first long-acting atypical antipsychotic medication dosed every two months.   In addition, Alkermes’ Phase III program for ALKS 5461, a Fast Track-designated drug...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters